Reduction of exercise-induced ventricular arrhythmias in mild symptomatic heart failure by benazepril

Am Heart J. 1993 Mar;125(3):771-6. doi: 10.1016/0002-8703(93)90169-a.

Abstract

We studied 14 patients who had exercise-induced ventricular arrhythmias after a previous Q-wave myocardial infarction. All had symptomatic mild heart failure in New York Heart Association class II and a maximal oxygen consumption between 16 and 20 ml/kg/min. They were treated with the angiotensin converting enzyme inhibitor benazepril (20 mg) and hydrochlorothiazide (50 mg) for 3 months in a double-blind randomized cross-over study. Benazepril improved the maximal oxygen uptake by 15% and exercise time by 18%. Hydrochlorothiazide slightly increased exercise time (5%) and the respiratory exchange ratio but not oxygen consumption. The arrhythmias were nonsustained and reproducible in two baseline recordings. Compared with baseline, benazepril reduced the mean number (3.5 +/- 2.5) (+/- SD) of episodes of ventricular tachycardia by 66%, and total (47.4 +/- 40.9) and paired (5.2 +/- 4.5) premature ventricular contractions by 61% and 62%, respectively. Hydrochlorothiazide did not reduce the number of arrhythmias. Thus an improved cardiac function induced by benazepril is associated with a reduction in exercise-induced ventricular arrhythmias in patients with symptomatic mild heart failure after infarction.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Benzazepines / therapeutic use*
  • Cardiac Complexes, Premature / etiology
  • Cardiac Complexes, Premature / prevention & control*
  • Double-Blind Method
  • Electrocardiography, Ambulatory
  • Exercise / physiology
  • Exercise Test
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Humans
  • Hydrochlorothiazide / therapeutic use*
  • Myocardial Infarction / complications
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / prevention & control*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • Hydrochlorothiazide
  • benazepril